[
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing > 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Patient demographic and baseline disease characteristics\n\n\nCharacteristics\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\n\n\nAge, years (mean ± SD)\n45.4 ± 14.1\n45.3 ± 14.2\n\n\nGender–male, n (%)\n356 (64.7)\n376 (68.1)\n\n\nRace–Caucasian, n (%)\n414 (75.3)\n410 (74.3)\n\n\n\nBody weight (mean ± SD)\n> 100 kg, n (%)\n\n\n91.0 ± 24.9\n189 (34.4)\n\n\n93.0 ± 24.9\n188 (34.1)\n\n\n\n\nPASI (mean ± SD)\nPASI > 20, n (%)\n\n\n20.8 ± 9.0\n210 (38.2)\n\n\n21.3 ± 9.2\n226 (40.9)\n\n\n\nBSA affected,  % (mean ± SD)\n29.2 ± 17.9\n29.5 ± 17.7\n\n\nIGA mod 2011—severe disease, n (%)\n209 (38.0)\n239 (43.3)\n\n\nMean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)\n16.8 ± 11.9\n17.3 ± 13.3\n\n\nPrevious exposure to biologic psoriasis therapy—yes, n (%)\n110 (20.0)\n130 (23.6)\n\n\n\nOpen in a new tab\nBSA body surface area, IGA mod 2011 Investigator’s Global Assessment 2011 modification, PASI Psoriasis Area and Severity Index, SD standard deviationEfficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Hierarchical efficacy analysis of key secondary objectives (% responders)\n\n\nParameters\nSecukinumab 300 mg (n = 550)\nUstekinumab 45/90 mg (n = 552)\n\np value\n\n\n\nPASI 75 at Week 12\n88.0%\n74.2%\n< 0.0001\n\n\nPASI 75 at Week 4\n40.2%\n16.3%\n< 0.0001\n\n\nPASI 90 at Week 16\n76.6%\n54.2%\n< 0.0001\n\n\nPASI 100 at Week 16\n45.3%\n26.7%\n< 0.0001\n\n\nIGA mod 2011 0/1 at Week 16\n78.6%\n59.1%\n< 0.0001\n\n\nPASI 100 at Week 12\n38.1%\n20.1%\n< 0.0001\n\n\nPASI 75 at Week 16\n91.7%\n79.8%\n< 0.0001\n\n\n\nOpen in a new tab\nIGA mod 2011 0/1 investigator’s global assessment 2011 modification clear (0) or almost clear (1), PASI psoriasis area and severity indexQuality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The rate of discontinuation was low and balanced between treatment arms (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Efficacy\nBoth co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Both co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; p < 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; p < 0.0001) (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Quality of Life\nThe proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; p < 0.0001), at Week 12 (64.0% vs. 51.7%; p < 0.0001), and at Week 16 (68.4% vs. 55.9%; p < 0.0001) (Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]